

NanoRegMed - Nanomédecine régénérative

Rapport Hcéres

► **To cite this version:**

Rapport d'évaluation d'une entité de recherche. NanoRegMed - Nanomédecine régénérative. 2017, Université de Strasbourg, Institut national de la santé et de la recherche médicale - INSERM. hceres-02030707

HAL Id: hceres-02030707

<https://hal-hceres.archives-ouvertes.fr/hceres-02030707>

Submitted on 20 Feb 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

HCERES

High Council for the Evaluation of Research
and Higher Education

Department of Research Evaluation

report on research unit:

Regenerative Nanomedecine

NanoRegMed

under the supervision of
the following institutions
and research bodies:

Université de Strasbourg

Institut National de la Santé Et de la Recherche
Médicale - INSERM

Evaluation Campaign 2016-2017 (Group C)

HCERES

High Council for the Evaluation of Research
and Higher Education

Department of Research Evaluation

In the name of HCERES,¹

Michel Cosnard, president

In the name of the experts committee,²

Marie-Christine Durrieu, chairwoman of the
committee

Under the decree No.2014-1365 dated 14 november 2014,

¹ The president of HCERES "countersigns the evaluation reports set up by the experts committees and signed by their chairman." (Article 8, paragraph 5)

² The evaluation reports "are signed by the chairman of the expert committee". (Article 11, paragraph 2)

Evaluation report

This report is the sole result of evaluation by the expert committee, the composition of which is specified below.

The assessments contained herein are the expression of an independent and collegial reviewing by the committee.

- Unit name: Regenerative Nanomedecine
- Unit acronym: NanoRegMed
- Label requested: UMR
- Current number: 1109
- Name of Director (2013-2017): Ms Nadia BENKIRANE-JESSEL
- Name of Project Leader (2018-2022): Ms Nadia BENKIRANE-JESSEL

Expert committee members

- Chair: Ms Marie-Christine DURRIEU, Université de Bordeaux
- Experts: Ms Magali CUCCHIARINI MADRY, Saarland University Medical Center, Germany
 Mr Frédéric CUISINIER, Université de Montpellier (representative of the CNU)
 Mr André PÉLEGRIN, Université de Montpellier (representative of the INSERM)
 Mr Laurent PLAWINSKI, Université de Bordeaux (representative of supporting personnel)
- Scientific delegate representing the HCERES: Ms Véronique MIGNONNEY
- Representatives of supervising institutions and bodies: Ms Catherine FLORENTZ, Université de Strasbourg
 Ms Meriem MAROUF-YORGOV, INSERM
 Ms Corinne TADDEI, Université de Strasbourg
- Head of Doctoral School: Mr Serge POTIER, ED n° 414, École Doctorale “Sciences de la vie et de la santé”

1 • Introduction

History and geographical location of the unit

The laboratory “Osteoarticular and Dental Regenerative Nanomedicine”, localized at 11, rue Humann Strasbourg, was created by INSERM and University of Strasbourg in January 2013 after positive evaluation by the AERES. INSERM and University of Strasbourg decided to create this team as an INSERM group, part of UMR 1109 “Immuno-Rhumatologie Moléculaire”. For the renewal of the laboratory, the proposed project entitled “Regenerative Nanomedicine” (NanoRegMed) is based on the team “Osteoarticular and Dental Regenerative Nanomedicine” managed by Ms Nadia BENKIRANE-JESSEL. In January 2018, this team will move to the new Building “CRBS” which will host all research units that are located currently in the old building of the Faculty of Medicine.

Currently, the team “Osteoarticular and Dental Regenerative Nanomedicine” has 3 internal groups: (i) Bone and Cartilage Regeneration; (ii) Tooth Engineering; (iii) Tooth and Surrounding Tissue Repair. In the next project, these 3 groups will merge in a single group, headed by Ms Nadia BENKIRANE-JESSEL, entitled “Osteoarticular and Dental Regenerative Nanomedicine” with all the above topics. In January 2018, 2 teams, one entitled “Experimental and Therapeutic Pharmacology”, headed by Ms Valérie SCHINI-KERTH, from the UMR CNRS 7213, Faculty of Pharmacy of the University of Strasbourg, and the second one headed by Ms Laurence KESSLER (EA 7293) will merge and join the unit to create group 2 entitled “Therapeutic Pharmacology and Vascular Regeneration” in a new single team.

Management team

The director is Ms Nadia BENKIRANE-JESSEL.

HCERES nomenclature

SVE5: Physiologie, Physiopathologie, Cardiologie, Pharmacologie, Endocrinologie, Cancer, Technologies Médicales (domaine principal).

Scientific domains

The main domain concerns smart hybrid materials, regenerative nanomedicine, and vascularisation.

Unit workforce

Unit workforce	Number on 30/06/2016	Number on 01/01/2018
N1: Permanent professors and similar positions	12 (ETP:3.93)	20 (ETP:6.4)
N2: Permanent researchers from Institutions and similar positions	2 (ETP:1.8)	4 (ETP:4)
N3: Other permanent staff (technicians and administrative personnel)	2 (ETP:2)	4 (ETP:4)
N4: Other researchers (Postdoctoral students, visitors, etc.)	3 (ETP:4)	
N5: Emeritus	2	
N6: Other contractual staff (technicians and administrative personnel)	1	
N7: PhD students	5	
TOTAL N1 to N7	27	
Qualified research supervisors (HDR) or similar positions	10	

Unit record	From 01/01/2011 to 30/06/2016
PhD theses defended	20
Postdoctoral scientists having spent at least 12 months in the unit	12
Number of Research Supervisor Qualifications (HDR) obtained during the period	5

2 • Assessment of the unit

Global assessment of the unit

The goal of the current application is to create a unique team with 2 main groups as to NanoMédecine Régénérative (NanoRegMed) based on the complementarity of two existing and well-recognized entities (Osteoarticular and Dental Regenerative Nanomedicine - group 1 head, Ms Nadia BENKIRANE-JESSEL; Therapeutic Pharmacology and Vascular Regeneration - group 2 head, Ms Valérie SCHINI-KERTH). The added value of combining the entities is highly promising and the organization of the new unit NanoRegMed (research themes and programs, competencies, objectives) is clearly defined and has a strong potential for success and high productivity. In January 2018, all this team will move to the new Building “CRBS” which will host all research units located today at the old building of the Faculty of Medicine.

The unit has a good capacity to obtain financial supports, to develop IP strategy and to federate high-risk projects and good expertise illustrated by the different national and international collaborations.

The gathering of all the members of this team in a same building (in January 2018) will consolidate the collaboration between the 2 groups.

The weak point could be the scientific animation and the coordination of the programs; this will be decisive for the sustainability of the laboratory. With the extension of members in the coming period, the NanoRegMed team should evaluate the potential risk of thematic dispersion. The presentation of the team in 2 groups, 4 themes, 3 programs is a little bit complicated (only programs are detailed). A number of PhD students and post-docs produce very few publications. Engineers and technicians are rarely involved in publications.